

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5480	(benzothiazole)".CLM"	US-PGPUB	OR	ON	2006/10/26 13:50
L2	5294	I1 and (acetic acid)".CLM"	US-PGPUB	OR	ON	2006/10/26 13:50
L3	1829	I2 and (carbamoyl)".CLM"	US-PGPUB	OR	ON	2006/10/26 13:51
L4	1170	I3 and (phenoxy)".CLM"	US-PGPUB	OR	ON	2006/10/26 13:51
S1	486	(548/180).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/10/26 13:36
S2	1051	(514/367).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/10/26 13:35
S3	2	("6420426").PN.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/10/26 13:50

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records  
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right  
truncation  
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced  
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine  
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new  
classification scheme  
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 13 OCT 19 E-mail format enhanced  
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available  
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in  
multiple databases  
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN  
has been enhanced and reloaded  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:05:43 ON 26 OCT 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION

FULL ESTIMATED COST

0.21 0.21

FILE 'REGISTRY' ENTERED AT 12:06:12 ON 26 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 OCT 2006 HIGHEST RN 911284-77-0  
DICTIONARY FILE UPDATES: 25 OCT 2006 HIGHEST RN 911284-77-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10662135.str



chain nodes :

7 8 9 10 11 13 18 21 22 23 24 28 29 30

ring nodes :

1 2 3 4 5 6

chain bonds :

6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:CLASS 13:CLASS 18:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:Atom

28:CLASS 29:CLASS 30:CLASS

Generic attributes :

18:

Number of Carbon Atoms : 7 or more

Number of Hetero Atoms : 2 or more

Type of Ring System : Polycyclic

Element Count :

Node 18: Limited

O,O0

S,S1

N,N1


C,C7

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:08:10 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 37169 TO ITERATE

5.4% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 731861 TO 754899  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:08:15 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 741560 TO ITERATE

98.8% PROCESSED 732431 ITERATIONS

103 ANSWERS



100.0% PROCESSED 741560 ITERATIONS  
SEARCH TIME: 00.00.18

103 ANSWERS

L3 103 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10662135.str



chain nodes :

7 8 9 10 11 13 18 21 22 23 24 28 29 30

ring nodes :

1 2 3 4 5 6

chain bonds :  
6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
exact/norm bonds :  
6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
isolated ring systems :  
containing 1 :


G1:O,S,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 13:CLASS 18:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:Atom  
28:CLASS 29:CLASS 30:CLASS  
Generic attributes :  
18:  
Number of Carbon Atoms : 7 or more  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Polycyclic

Element Count :  
Node 18: Limited  
O,O0  
S,S1  
N,N1  
C,C7

L4 STRUCTURE UPLOADED

=>  
=> d  
L4 HAS NO ANSWERS  
L4 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 12:28:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 89058 TO ITERATE

2.2% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*

PROJECTED ITERATIONS: 1763435 TO 1798885  
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> d his

(FILE 'HOME' ENTERED AT 12:05:43 ON 26 OCT 2006)

FILE 'REGISTRY' ENTERED AT 12:06:12 ON 26 OCT 2006

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 103 S L1 FULL

L4 STRUCTURE UPLOADED

L5 0 S L4

=> s l3 and caplus/lc

52481958 CAPLUS/LC


L6 85 L3 AND CAPLUS/LC

=> s l3 not l6

L7 18 L3 NOT L6

=> d l7 18

L7 ANSWER 18 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165948-81-2 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, 2,2'-[[4-[[methyl[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)  
 MF C21 H22 N2 O8 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




=> d 17 1-18

L7 ANSWER 1 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 865428-58-6 REGISTRY  
 ED Entered STN: 18 Oct 2005  
 CN Acetic acid, [4-[3-(2-benzothiazolylamino)-2-cyano-3-oxo-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C19 H13 N3 O4 S  
 SR Chemical Library  
 Supplier: TimTec, Inc.  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 2 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 865428-56-4 REGISTRY  
 ED Entered STN: 18 Oct 2005  
 CN Acetic acid, [3-[3-(2-benzothiazolylamino)-2-cyano-3-oxo-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C19 H13 N3 O4 S  
 SR Chemical Library  
 Supplier: TimTec, Inc.  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 3 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 766490-01-1 REGISTRY  
 ED Entered STN: 21 Oct 2004  
 CN Acetic acid, [4-[1-(3-pyridinyloxy)-2-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]ethyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)  
 MF C25 H27 N3 O5 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 4 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 197237-52-8 REGISTRY  
 ED Entered STN: 13 Nov 1997  
 CN Acetic acid, [4-[2-[methyl[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]-1-(3-pyridinyloxy)ethyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C24 H25 N3 O5 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 5 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 197237-42-6 REGISTRY  
 ED Entered STN: 13 Nov 1997  
 CN Acetic acid, [4-[1-(3-pyridinyloxy)-2-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]ethyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C23 H23 N3 O5 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 6 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 197237-40-4 REGISTRY  
 ED Entered STN: 13 Nov 1997  
 CN Acetic acid, 2,2'-[[4-[1-(3-pyridinyloxy)-2-[methyl[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]ethyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)  
 MF C26 H27 N3 O8 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 7 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 197237-38-0 REGISTRY  
 ED Entered STN: 13 Nov 1997  
 CN Acetic acid, 2,2'-[[4-[1-(3-pyridinyloxy)-2-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]ethyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)  
 MF C25 H25 N3 O8 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 8 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 197237-36-8 REGISTRY  
 ED Entered STN: 13 Nov 1997  
 CN Acetic acid, [2-[(3-pyridinyloxy)methyl]-4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]phenoxy]- (9CI)  
 (CA INDEX NAME)  
 MF C24 H23 N3 O6 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 9 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 197237-34-6 REGISTRY  
 ED Entered STN: 13 Nov 1997  
 CN Acetic acid, [2-[(1H-imidazol-1-ylmethyl)-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI)  
 (CA INDEX NAME)  
 MF C22 H22 N4 O5 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 10 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165949-36-0 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, [2-[[[(ethylamino)carbonyl]oxy]-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI)  
 (CA INDEX NAME)  
 MF C21 H23 N3 O7 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 11 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165949-34-8 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, [2-hydroxy-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C18 H18 N2 O6 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 12 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165949-31-5 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, [2-(carboxymethoxy)-5-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]-, 1-ethyl ester (9CI) (CA INDEX NAME)  
 MF C22 H24 N2 O8 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 13 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165949-29-1 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, [2-(phenylmethoxy)-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C25 H24 N2 O6 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 14 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165949-27-9 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, [2-propoxy-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C21 H24 N2 O6 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 15 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165949-13-3 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis-, bis[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl] ester (9CI) (CA INDEX NAME)  
 MF C30 H28 N2 O14 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 16 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165948-95-8 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, [3-methoxy-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C19 H20 N2 O6 S  
 CI COM  
 SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 17 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165948-91-4 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, [3-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)  
 MF C18 H18 N2 O5 S  
 CI COM  
 SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 ANSWER 18 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 165948-81-2 REGISTRY  
 ED Entered STN: 09 Aug 1995  
 CN Acetic acid, 2,2'-[[4-[[methyl[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)  
 MF C21 H22 N2 O8 S  
 CI COM  
 SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> fil caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
224.52	224.73

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:29:51 ON 26 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2006 VOL 145 ISS 18  
FILE LAST UPDATED: 25 Oct 2006 (20061025/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 12:05:43 ON 26 OCT 2006)

FILE 'REGISTRY' ENTERED AT 12:06:12 ON 26 OCT 2006

L1	STRUCTURE UPLOADED
L2	0 S L1
L3	103 S L1 FULL
L4	STRUCTURE UPLOADED
L5	0 S L4
L6	85 S L3 AND CAPLUS/LC
L7	18 S L3 NOT L6

FILE 'CAPLUS' ENTERED AT 12:29:51 ON 26 OCT 2006

=> s l6

L8 15 L6

=> d ibib abs hitstr 1-15

L8 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2005:1021642 CAPLUS  
DOCUMENT NUMBER: 143:311996  
TITLE: Methods for inhibiting platelet activation and aggregation, and therapeutic uses for conditions or surgical procedures that may result in unwanted platelet aggregation  
INVENTOR(S): Porter, Stephen R.; Flaharty, Kristen K.; Tchong, James E.; Ferkany, John W.  
PATENT ASSIGNEE(S): Vvdi Pharmaceuticals, USA  
SOURCE: PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087266	A1	20050922	WO 2005-US7440	20050307
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, T2, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-550792P P 20040305


AB The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the i.v., s.c., or transdermal administration of a platelet activation or aggregation inhibitor, e.g., ximilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.

IT 165948-72-1, ME 3277

RL: ANT (Analyte); ANST (Analytical study)  
(combination therapy for inhibition of platelet aggregation)

RN 165948-72-1 CAPLUS

CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2005:352316 CAPLUS  
DOCUMENT NUMBER: 143:109373  
TITLE: Lack of Improvement of Oral Absorption of ME3277 by Prodrug Formation Is Ascribed to the Intestinal

Efflux

Mediated by Breast Cancer Resistant Protein

(BCRP/ABCG2)

AUTHOR(S): Kondo, Chihiko; Onuki, Reiko; Kusuhashi, Hiroyuki; Suzuki, Hiroshi; Suzuki, Michiko; Okudaira, Noriko; Kojima, Maho; Ishiwata, Kazuya; Jonker, Johan W.; Sugiyama, Yuichi  
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Hongo, Bunkyo-ku, 113-0033, Japan  
SOURCE: Pharmaceutical Research (2005), 22(4), 613-618  
CODEN: PHREB; ISSN: 0724-8741

PUBLISHER: Springer

DOCUMENT TYPE: Journal

LANGUAGE: English

AB ME3229, an ester-type prodrug of a hydrophilic glycoprotein Iib/IIIa antagonist (ME3277), failed to show improved oral absorption. Okudaira

et al. (J. Pharmacol. Exp. Ther. 294, 580-587, 2000) provided a piece of evidence that this is ascribed to an efflux system, distinct from P-gp

and MRP2, that extrudes ME3277 formed from ME3229 in the intestinal

epithelial cells. The aim of the present study is to examine the involvement of breast cancer resistant protein (BCRP/ABCG2) as a cause of low oral absorption of ME3229. The transport activity of ME3277 in the presence and absence of ATP was determined using a rapid filtration method with

the membrane vesicles prepared from LLC-PK1 cells expressing BCRP. The

plasma concns. of ME3229 and its metabolites were compared between Bcrp1-/- mice and wild-type mice after a single-pass perfusion of small intestine with ME3229. The ATP-dependent uptake of ME3277 was greater in

BCRP-expressing membrane vesicles than that in the control vesicles. Furthermore, it was found that after intestinal perfusion with ME3229 for 60 min, the plasma concns. of ME3277 and PM-3, a metabolite of ME3229, increased 2-fold and 3-fold, resp., in Bcrp1 knockout mice. It is possible that BCRP acts synergistically with intestinal carboxylesterases. These results suggest that Bcrp1 plays an important role in the intestinal efflux of ME3277

and, probably, PM-10 and PM-11, metabolites of ME3229, and limits its BA after oral administration of ME3229.

IT 165949-19-9 207463-37-4 207463-42-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to intestinal efflux mediated by breast cancer resistant protein BCRP/ABCG2)

RN 165949-19-9 CAPLUS


CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]ethyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L8 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 207463-37-4 CAPLUS

CN Acetic acid,


[2-(2-butoxy-2-oxoethoxy)-4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 207463-42-1 CAPLUS

CN Acetic acid,

[2-(2-butoxy-2-oxoethoxy)-5-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 165948-72-1, ME3277 165949-40-6, ME3229

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to intestinal efflux mediated by breast cancer resistant protein BCRP/ABCG2)


RN 165948-72-1 CAPLUS

CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)






RN 165949-40-6 CAPLUS  
CN Acetic acid, 2,2'-[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)bis-, dibutyl ester (9CI)  
(CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS  
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


ACCESSION NUMBER: 2004:819180 CAPLUS  
DOCUMENT NUMBER: 141:374428  
TITLE: Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications  
AUTHOR(S): Van Zandt, Michael C.; Sibley, Evelyn O.; McCann, Erin  
CORPORATE SOURCE: E.; Combs, Kerry J.; Flam, Brenda; Sawicki, Diane R.; Sabetta, Al; Carrington, Anne; Sredy, Janet; Howard, Eduardo; Mitschler, Andre; Podjarny, Alberto D. The Institute for Diabetes Discovery, LLC, Branford, CT, 06405, USA  
SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(21), 5661-5675  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:374428  
GI




AB Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid aldose reductase inhibitors. The compound class features a core template that utilizes an intramol. hydrogen bond to position the key structural elements of the pharmacophore in a conformation, which promotes a high binding affinity. The lead candidate, I, 5-fluoro-2-(4-bromo-2-fluoro-benzylthiocarbamoyl)-phenoxyacetic acid, inhibits aldose reductase with an IC50 of 30 nM, while being 1100 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. In addition, I lowers nerve sorbitol levels with an ED50 of 31 mg/kg/d po in the 4-day ST2-induced diabetic rat model.  
IT 314297-79-5P 314297-80-8P 314297-81-9P 314297-82-0P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(design and synthesis of (arylcarbamoylphenoxy)acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications)  
RN 314297-79-5 CAPLUS  
CN Acetic acid, [5-fluoro-2-[[[4,5,7-trifluoro-2-




RN 314297-80-8 CAPLUS  
CN Acetic acid, [5-fluoro-2-[[[4,5,7-trifluoro-2-benzothiazolyl]methyl]amino]methyl]phenoxy]- (9CI)  
(CA INDEX NAME)



RN 314297-81-9 CAPLUS  
CN Acetic acid, [5-fluoro-2-[[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]amino]carbonyl]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 314297-82-0 CAPLUS  
CN Acetic acid, [5-chloro-2-[[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]amino]carbonyl]phenoxy]- (9CI)  
(CA INDEX NAME)



IT 314298-38-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(design and synthesis of (arylcarbamoylphenoxy)acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications)  
RN 314298-38-9 CAPLUS

CN Acetic acid, [5-fluoro-2-[[[4,5,7-trifluoro-2-benzothiazolyl]methyl]amino]carbonyl]phenoxy]-, ethyl ester (9CI)  
(CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS  
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER: 2004:583377 CAPLUS  
DOCUMENT NUMBER: 142:142124  
TITLE: The crystallographic structure of the aldose  
reductase-IDS552 complex shows direct proton donation  
from tyrosine 48  
AUTHOR(S): Ruiz, Federico; Hazemann, Isabelle; Mitschler, Andre;  
Joachimiak, Andrzej; Schneider, Thomas; Karplus,  
Martin; Podjarny, Alberto  
CORPORATE SOURCE: IGBMC, CNRS INSERM ULP, UPR de Biologie Structurale,  
Illkirch, 67404, Fr.  
SOURCE: Acta Crystallographica, Section D: Biological  
Crystallography (2004), D60(8), 1347-1354  
CODEN: ABCREB; ISSN: 0907-4449  
PUBLISHER: Blackwell Publishing Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The x-ray crystal structure of human aldose reductase (ALR2) in complex with the inhibitor IDD552 was determined using crystals obtained from two crystallization conditions with different pH values (pH 5 and 8). In


structures the charged carboxylic head of the inhibitor binds to the active site, making hydrogen-bond interactions with His10 and Tyr48 and electrostatic interactions with NADP<sup>+</sup>. There is an important difference between the two structures: the observation of a double conformation of the carboxylic acid moiety of the inhibitor at pH 8, with one water mol. interacting with the main configuration. This is the first time that a water mol. has been observed deep inside the ALR2 active site.

Furthermore, in the configuration with the lower occupancy factor the difference electron-density map shows a clear peak (2.5σ) for the H atom in the hydrogen bond between the inhibitor and the Tyr48 side-chain O atom. The position of this peak implies that this H atom is shared between both O atoms, indicating possible direct proton transfer from this residue to the inhibitor. This fact agrees with the model of the catalytic mechanism, in which the proton is donated by the Tyr48 hydroxyl to the catalytic residue. These observations are useful both in drug design and in understanding the Aβ2 mechanism.

IT design and in understanding the ADAR mechanism.  
314297-79-5D, IDD 552, complex with aldose reductase  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
(Biological study)  
(crystallog. structure of aldose reductase-IDD552 complex shows direct  
proton donation from tyrosine 48)

proton donation  
RN 314297-79-5 CAPLUS

Acetic acid, [5-fluoro-2-[[[(4,5,7-trifluoro-2-benzothiazolyl)methyl]amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR

THIS

### FORMAT

L8 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:315488 CAPLUS  
DOCUMENT NUMBER: 135:116938  
TITLE: Thromboxane A2 synthase inhibitor enhanced  
antithrombotic efficacy of GPIIb-IIIa receptor  
antagonist without increasing bleeding  
AUTHOR(S): Kawano, K.-I.; Hokamure, K.; Kondo, K.; Ikeda, Y.

**CORPORATE SOURCE:** SUZUKI, Y.; UMEMURA, K.  
Department of Pharmacology, Hamamatsu University  
School of Medicine, Hamamatsu, 431-3192, Japan

**SOURCE:** European Journal of Pharmacology (2001), 417(3),  
217-222

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB: The advantage of platelet integrin GPIIb-IIIa receptor antagonists in the

AB The advantage of platelet integrin GPIIb-IIIa receptor antagonists in the prevention of thrombotic occlusion was clearly proven in patients who underwent interventional treatment of the coronary artery, but its value in cerebral ischemia is still under investigation. The expectation of antithrombotic effect of GPIIb-IIIa receptor antagonist in the treatment of cerebral ischemia restricts its application in cerebral ischemia. To minimize bleeding while keeping antithrombotic activity, we have tried to find an appropriate approach using a combination of platelet integrin GPIIb-IIIa receptor antagonist and some other antithrombotic agents. The time to thrombotic occlusion was prolonged using a combination of antithrombotic occlusion model of guinea pig middle cerebral artery. Platelet integrin GPIIb-IIIa receptor antagonist, ME3277, sodium hydrogen

[4-] [(4,5,6,7-tetrahydrothieno [3,2-c] pyridin-2-yl) carbonylamino] acetyl-o-phenylene] dioxydiacetate], delayed occlusion time from 7.3 min in vehicle to 15.0, 20.6 and 25.9 min (PC.O.05) at 0.1, 0.3 and 1 mg/kg, resp. ME3277 profoundly inhibited ex vivo platelet aggregation and the highest dose of ME3277 prolonged (3.5 folds, PC.O.01) the bleeding time measured in the hind paw. A thromboxane A2 synthase inhibitor, sodium ozagrel, significantly delayed occlusion time to 19.5 min at 30 mg/kg (PC.O.05) while it did not affect bleeding time or platelet aggregation. ME3277 (0.1 mg/kg) in combination with 10 mg/kg sodium ozagrel synergistically delayed occlusion time (sodium ozagrel alone: 7.9 min, combination: 26.1 min, PC.O.05 vs. ME3277 alone). Sodium ozagrel did not affect ex vivo platelet aggregation or bleeding time when combined with 0.1 mg/kg of ME3277. This synergy was cancelled by combination with 30 mg/kg aspirin (7.7 min). A thromboxane A2 receptor antagonist, vaprost (0.1 mg/kg) did not enhance the antithrombotic effect of ME3277. These results imply that local prostacyclin production enhances the in vivo antithrombotic effect of the platelet integrin GPIIb-IIIa receptor antagonist. Therefore, the thromboxane A2 synthase inhibitor, allowed a reduction in the dose level


platelet integrin GPIIb-IIIa receptor antagonist for cerebral thrombosis, which resulted in a reduced risk of bleeding.

IT 165948-72-1, ME3277  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

(Uses)  
(thromboxane A2 synthase inhibitor enhanced antithrombotic efficacy of  
GPIIb-IIIa receptor antagonist without increasing bleeding)

GR1B-11a receptor antagonist without increasing bleeding)  
RN 165948-72-1 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX

L8 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

### FORMAT

ACCESSION NUMBER: 2001:12407 CAPLUS

DOCUMENT NUMBER: 134:71392

TITLE:

Preparation and effect of Substituted phenoxyacetic acids in complications arising from diabetes mellitus

INVENTOR(S): Van Zandt, Michael C.

PATENT ASSIGNEE(S): The Institutes for Pharmaceutical Discovery, LLC, USA

SOURCE:

DOCUMENT TYPE:

LANGUAGE:


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000566	A2	20010104	WO 2000-US17377	20000623
WO 2001000566	A3	20020207		
W:	AZ, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2385798	AA	20010104	CA 2000-2385798	20000623
BR 2000011928	A	20020409	BR 2000-11928	20000623
EP 1198451	A2	20020424	EP 2000-944834	20000623
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL			
US 6420426	B1	20020716	US 2000-603817	20000623
JP 200303381	T2	20030128	JP 2001-506979	20000623
EE 200100708	A	20030217	EE 2001-708	20000623
NZ 516290	A	20040326	NZ 2000-516290	20000623
NO 200106272	A	20020117	NO 2001-6272	20011220
ZA 2002000300	A	20030613	ZA 2002-300	20020114
BG 106351	A	20020930	BG 2002-106351	20020125
US 2003036558	A1	20030220	US 2002-195964	20020716
US 2005239849	A1	20051027	US 2003-662135	20030912
PRIORITY APPLN. INFO.:			US 1999-141068P	P 19990625
			US 2000-603817	A3 20000623
			WO 2000-US17377	W 20000623
			US 2002-195964	B1 20020716

OTHER SOURCE(S): MARPAT 134:71392

GI



AB Disclosed are substituted phenoxyacetic acids I; R = OH, OCH<sub>2</sub>CH<sub>3</sub>, C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>O, (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>CH<sub>2</sub>O, CH<sub>3</sub>(CH<sub>2</sub>)<sub>7</sub>O, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>; R<sub>1</sub> = H, Cl, F, Br, CH<sub>3</sub>O, CH<sub>3</sub>, NO<sub>2</sub>, CH<sub>3</sub>S, CF<sub>3</sub>, CH<sub>3</sub>SO<sub>2</sub>; R<sub>2</sub> = F, H; R<sub>3</sub> = Br, H, Cl, CH<sub>3</sub>O, CF<sub>3</sub>O, CH<sub>3</sub>; R<sub>4</sub> = H, F, CF<sub>3</sub>, NO<sub>2</sub>, CH<sub>3</sub>O, Cl; R<sub>5</sub> = H, F; R<sub>6</sub> = H, F, CF<sub>3</sub>, CH<sub>3</sub>O; R<sub>7</sub> = H, CH<sub>3</sub>, CF<sub>3</sub>, NH<sub>2</sub>, F; R<sub>8</sub> = H, F; X = O, S; etc.] useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compns. containing title compds. I, alone or in combination with other therapeutic agents, and methods of treatment employing the compds. and pharmaceutical compns., as well as methods for their synthesis. The pharmaceutical composition contains angiotensin converting enzyme inhibitor (benazepril, captopril, delapril, etc). Thus, title compound I (R<sub>1</sub> = Cl; R = OH; X = O; R<sub>4</sub> = NO<sub>2</sub>; R<sub>2</sub>, R<sub>3</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> each = H) was prepared and tested.


IT 314298-38-9P 314298-39-OP

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and effect of substituted phenoxyacetic acids in complications arising from diabetes mellitus)


RN 314298-38-9 CAPLUS

CN Acetic acid, [5-fluoro-2-[[[(4,5,7-trifluoro-2-benzothiazolyl)methyl]amino]carbonyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 314298-39-0 CAPLUS

CN Acetic acid, [5-fluoro-2-[[[(4,5,7-trifluoro-2-benzothiazolyl)methyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



IT 314297-79-5P 314297-80-8P 314297-81-9P


314297-82-OP

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and effect of substituted phenoxyacetic acids in complications arising from diabetes mellitus)


RN 314297-79-5 CAPLUS

CN Acetic acid, [5-fluoro-2-[[[(4,5,7-trifluoro-2-benzothiazolyl)methyl]amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 314297-80-8 CAPLUS

CN Acetic acid, [5-fluoro-2-[[[(4,5,7-trifluoro-2-benzothiazolyl)methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 314297-81-9 CAPLUS

CN Acetic acid, [5-fluoro-2-[[[(4,5,7-trifluoro-2-benzothiazolyl)methyl]amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 314297-82-0 CAPLUS

CN Acetic acid, [5-chloro-2-[[[(5-(trifluoromethyl)-2-benzothiazolyl)methyl]amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2000:779756 CAPLUS

DOCUMENT NUMBER: 134:80492

TITLE: Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIB/IIIA receptor antagonist, in rat small intestine

AUTHOR(S): Okuda, Noriko; Komiya, Izumi; Sugiyama, Yuichi

CORPORATE SOURCE: Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., Yokohama, Japan

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2000), 295(2), 717-723

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB ME3229 is an ester-type prodrug of a glycoprotein IIB/IIIA receptor antagonist ME3277. In our previous study, it was shown that only a small part of the drug taken up into the enterocytes reached the mesenteric vein, mainly due to transporter-mediated efflux of its hydrolyzed metabolites formed in the cells. To characterize the efflux transport system for the metabolites, the transport of the diacid metabolite ME3277 and the monoacid metabolites PM-10 and PM-11 were studied. ME3277 and PM-10 were preferentially transported in the serosal-to-mucosal direction across the rat small intestine in the presence of glucose. Permeability of ME3277 across monolayer of Caco-2 cells with P-glycoprotein (P-gp) and indomethacin-sensitive efflux pump expression did not show any directionality and verapamil, an inhibitor of P-gp, and indomethacin did not affect the permeability of ME3277 across rat intestinal tissue. Directional transport was not site specific and was observed in the Eisai hyperbilirubinemic rat whose canalicular multispecific organic anion transporter/multidrug resistance-associated protein (cMOAT/MRP2) is hereditarily defective as well as in normal rats. The efflux transport

of ME3277 was inhibited by 1-naphthol, 1-chloro-2,4-dinitrobenzene, and sulfbromophthalein, and efflux of ME3277 and monoacid metabolites from intestinal tissue preloaded with ME3229 fell in the presence of 1-naphthol and sulfbromophthalein. These results demonstrate that mono- and diacid metabolites of ME3229 were pumped out into the gut lumen by an energy-dependent transport system located on the mucosal membrane of intestinal tissue and distinct from either P-gp, indomethacin-sensitive efflux pump or canalicular multispecific organic anion transporter/MRP2.

An inhibition study suggested that this unknown transporter has a substrate specificity similar to that of MRP transporter families.

IT 316831-57-9, EF 5139


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (effect of EF5139 on transport of ME3277 from mucosal to serosal surface of small intestine)

RN 316831-57-9 CAPLUS

CN Acetic acid, 2,2'-[[4-[[[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis-, dibutyl ester (9CI)

(CA INDEX NAME)


(Continued)



RN 207463-42-1 CAPLUS


CN Acetic acid, [2-(2-butoxy-2-oxoethoxy)-5-[[[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI)

(CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE



IT 165948-72-1, ME3277 165949-40-6, ME 3229


207463-37-4 207463-42-1

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (polarized efflux of mono- and diacid metabolites of ME3229 in small intestine)

RN 165948-72-1 CAPLUS

CN Acetic acid, 2,2'-[[4-[[[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI)


(CA INDEX NAME)



RN 165949-40-6 CAPLUS

CN Acetic acid, 2,2'-[[4-[[[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis-, dibutyl ester (9CI)

(CA INDEX NAME)



RN 207463-37-4 CAPLUS

CN Acetic acid, [2-(2-butoxy-2-oxoethoxy)-4-[[[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI)

(CA INDEX NAME)

ACCESSION NUMBER: 2000:536330 CAPLUS

DOCUMENT NUMBER: 134:157153

TITLE: A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as

a

AUTHOR(S): Okuda, Noriko; Tatebayashi, Tomoko; Speirs, Graham C.; Komiya, Izumi; Sugiyama, Yuichi

CORPORATE SOURCE: Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., Yokohama, Japan

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2000), 294(2), 580-587

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The intestinal absorption of a prodrug is affected by a number of factors, such as its membrane permeability, stability in the gut lumen, and conversion to the parent drug in enterocytes. We evaluated the

absorption of ME3229, an ester-type prodrug of a hydrophilic glycoprotein IIB/IIIA antagonist. Although the octanol/water distribution coefficient and permeability across a Caco-2 cell monolayer of ME3229 was high enough for us to expect good oral absorption, less than 10% of the dose was absorbed in rats. To clarify this unexpected outcome, we evaluated the rate of

its disappearance from the gut lumen (V1), its degradation in the gut lumen (Vdeg), uptake into enterocytes (Vuptake), and appearance in the mesenteric vein (V2) by using a single-pass perfusion technique in combination with an in vitro metabolism study. Our data suggested that

ME3229 crossed the apical membrane and was taken up into enterocytes at a rate compatible with its lipophilicity, but that only a small fraction of the metabolites formed in enterocytes reached the mesenteric vein, primarily attributable to efflux into the intestinal lumen. Transport of the main metabolite across rat intestinal tissue mounted on an Ussing chamber suggested that an active efflux system pumped out any ionic metabolite(s) present.


165949-40-6, ME 3229

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (intestinal absorption of prodrug, ME3229, in rats)


RN 165949-40-6 CAPLUS

CN Acetic acid, 2,2'-[[4-[[[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis-, dibutyl ester (9CI)

(CA INDEX NAME)



IT 165948-72-1, ME3277  
 RL: BPR (Biological process); BSU (Biological study, unclassified); MPM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)  
 (intestinal absorption of prodrug, ME3229, in rats)  
 RN 165948-72-1 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy))bis- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

ACCESSION NUMBER: 2000:438304 CAPLUS  
 DOCUMENT NUMBER: 133:305420  
 TITLE: ME3277, a GPIIb/IIIa antagonist, reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery  
 AUTHOR(S): Kawano, Ken-Ichi; Fujishima, Kazuyuki; Ikeda, Yasuhiko; Kondo, Kazunao; Umemura, Kazuo  
 CORPORATE SOURCE: Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan  
 SOURCE: Journal of Cerebral Blood Flow and Metabolism (2000), 20(6), 988-997  
 CODEN: JCBMDN; ISSN: 0271-678X  
 PUBLISHER: Lippincott Williams & Wilkins  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB A rabbit focal thrombotic occlusion model of the middle cerebral artery was established by creating a photochem. reaction between green light and Rose Bengal. Hemorrhagic transformation was common in the area of cerebral infarction. In this model, the effect of the glycoprotein IIb/IIIa (GPIIb/IIIa) antagonist ME3277 (0.15 mg/kg bolus plus 0.125 mg/kg/h; 0.3 mg/kg plus 0.25 mg/kg/h; or 0.6 mg/kg plus 0.5 mg/kg/h), aspirin (20 mg/kg) and sodium ozagrel (thromboxane A2 synthase inhibitor, 1 mg/kg plus 2 mg/kg/h) were evaluated. The drugs were given i.v. for 24 h, starting 30 min after the photochem. reaction. Aspirin inhibited the platelet aggregation induced ex vivo by arachidonic acid and collagen but not that by ADP, while sodium ozagrel inhibited only the arachidonic acid-induced aggregation. ME3277 dose-dependently inhibited the platelet aggregation elicited by all the inducers. After 24 h of middle cerebral artery occlusion, infarct volume was reduced by aspirin and each dose of ME3277. These agents improved neurol. deficits, with ME3277 being more potent than aspirin. Sodium ozagrel did not alter the infarct volume or neurol. deficits. None of the drugs worsened hemorrhage volume despite increasing bleeding time (2-3 fold) in the skin. In this model, the occluded artery was spontaneously rechanneled and rethrombosed frequently.

One mechanism by which the antiplatelet agents reduced infarct volume was by inhibition of rethrombosis of the artery. These results suggest that treatment with a GPIIb/IIIa antagonist is a useful intervention for acute cerebral infarction.

IT 165948-72-1, ME 3277  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)  
 (glycoprotein IIb/IIIa antagonist ME3277 reduction of cerebral artery infarction without enhancing intracranial hemorrhage)

RN 165948-72-1 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy))bis- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT


ACCESSION NUMBER: 1999:672794 CAPLUS  
 DOCUMENT NUMBER: 131:286539  
 TITLE: Preparation of nitrogen-containing heterocyclic compounds as platelet aggregation inhibitors  
 INVENTOR(S): Ota, Kazumi; Kobayashi, Kazuko; Miura, Tomoaki; Imai, Takahiro; Aizawa, Kazumasa; Suzuki, Hisahi; Ohuchi, Shokichi; Katano, Kiyooki; Ando, Takashi  
 PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan  
 SOURCE: PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9952894	A1	19991021	WO 1998-JP2641	19980616
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9876757	A1	19991101	AU 1998-76757	19980616
EP 1070712	A1	20010124	EP 1998-924636	19980616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6472397	B1	20021029	US 2000-647849	20001103
PRIORITY APPLN. INFO.:			JP 1998-97051	A 19980409
			WO 1998-JP2641	W 19980616

OTHER SOURCE(S): MARPAT 131:286539  
 GI



II




III

AB Title compds. I (A = CH<sub>2</sub>, CO; B = (CH<sub>2</sub>)<sub>k</sub>, (CH<sub>2</sub>)<sub>m</sub>CO; X, Y are different from each other and each represents N or CH; W represents a group which can be eliminated under physiol. conditions; Z = II, III; D = V(CH<sub>2</sub>)<sub>p</sub>COOR;

V = O or bond; R, R<sub>1</sub> = H, alkyl; k = 1-4; m = 0-3; n = 1-3; p = 1-4) and their pharmacol. acceptable salts, useful as platelet aggregation inhibitors and for the treatment of thrombosis, are prepared. Thus, reaction of Et 4-[[2-oxo-4-(piperidin-4-yl)piperazin-1-yl]acetyl]phenoxyacetate dihydrochloride with chloromethyl chloroformate in CH<sub>2</sub>Cl<sub>2</sub> in the presence of Et<sub>3</sub>N gave Et 4-[[4-(1-chloromethoxycarbonylpiperidin-4-yl)-2-oxopiperazin-1-yl]acetyl]phenoxyacetate, reaction of which with AcOH in DMF in the presence of K<sub>2</sub>CO<sub>3</sub> gave Et 4-[[4-(1-acetoxymethoxycarbonylpiperidin-4-yl)-2-oxopiperazin-1-yl]acetyl]phenoxyacetate (IV). IV had good bioavailability with 36.9% B.A. in rats.


IT 246024-19-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of nitrogen-containing heterocyclic compds. as platelet aggregation inhibitors)

RN 246024-19-1 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis-, diethyl ester (9CI)  
(CA INDEX NAME)



IT 246024-20-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of nitrogen-containing heterocyclic compds. as platelet aggregation inhibitors)

RN 246024-20-4 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis(2-ethoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1-(acetoxy)ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

ACCESSION NUMBER: 1999:466657 CAPLUS  
DOCUMENT NUMBER: 131:208831  
TITLE: Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery  
AUTHOR(S): Kawano, Ken-Ichi; Ikeda, Yasuhiko; Kondo, Kazunao; Umemura, Kazuo  
CORPORATE SOURCE: Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan  
SOURCE: European Journal of Pharmacology (1999), 374(3), 377-385  
CODEN: EJPHAZ; ISSN: 0014-2999  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB We established a photothrombotic occlusion model in the guinea pig middle cerebral artery. In this model, the middle cerebral artery was recanalized within 10 to 20 min after thrombotic occlusion, with subsequent cyclic flow redns. Cyclic flow redns. in the middle cerebral artery are expected to manage cerebral infarction by modulating arterial patency. Therefore, we evaluated the effect of several antiplatelet agents on the frequency of cyclic flow redns. and subsequent cerebral infarction using this model. A platelet integrin GPIIb-IIIa receptor antagonist, ME3277 (sodium hydrogen [4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-o-phenylene]dioxylate, 0.3, 1 and 3 mg/kg i.v.) dose-dependently inhibited the


ex vivo platelet aggregation induced by ADP (5 μM), collagen (0.8 and 20 μg/mL) and arachidonic acid (100 μM). While the same doses of ME3277 reduced the frequency of the cyclic flow redns. and increased the total patency time of the middle cerebral artery, time to thrombotic occlusion was prolonged only at the highest dose, 3 mg/kg. ME3277 (0.3-3 mg/kg) significantly reduced the infarct volume and improved the neurol. deficit at 24 h. In contrast, aspirin (30 mg/kg) did not affect these variables in spite of complete inhibition of platelet aggregation induced by arachidonic acid and collagen (0.8 μg/mL). A thromboxane A<sub>2</sub> synthetase inhibitor, sodium ozagrel, significantly increased the total patency time and reduced the infarct volume at 30 mg/kg. Inhibition of prostaglandin I<sub>2</sub> generation could explain the effectiveness of sodium ozagrel but not aspirin in this model. These results suggest that platelet integrin GPIIb-IIIa receptor antagonists are more beneficial

than aspirin for the treatment of cerebral thrombosis.

IT 165948-72-1, ME3277  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)  
(platelet integrin GPIIb-IIIa receptor antagonist vs. aspirin and ozagrel in preventing cyclic flow redns. in middle cerebral artery)

RN 165948-72-1 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L8 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1998:236776 CAPLUS  
 DOCUMENT NUMBER: 129:595  
 TITLE: Thienopyridine derivatives and antithrombotics  
 containing them  
 INVENTOR(S): Ota, Kazumi; Tasomura, Yasuko; Ishikawa, Minoru;  
 Okudaira, Noriko; Suzuki, Takeshi; Aisawa, Kazumasa;  
 Katano, Kiyooki  
 PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.  
 CODEN: JKOKXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10101677	A2	19980421	JP 1996-258031	19960930
PRIORITY APPLN. INFO.:			JP 1996-258031	19960930

OTHER SOURCE(S): MARPAT 129:595  
 GI



AB The title derivs. I (one of R1 and R2 = H, and the other = lower alkyl' X = CO, CHO), their pharmacol. acceptable salts, or their solvates are prepared Also claimed are therapeutic agents for thrombotic diseases containing

I, their salts, or their solvates. I (X = CO, R1 = Bu, R2 = H), prepared from chloroacetyl catechol with 6 steps, inhibited ADP-induced aggregation of human platelets at IC50 5.0 + 10-7M.

IT 207463-37-4P 207463-41-0P 207463-42-1P

207463-49-8P 207463-59-0P

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of thienopyridine derivs. as antithrombotics)

RN 207463-37-4 CAPLUS

CN Acetic acid,


[2-(2-butoxy-2-oxoethoxy)-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)

L8 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 207463-49-8 CAPLUS

CN Acetic acid, [2-(2-butoxy-2-oxoethoxy)-4-[1-hydroxy-2-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 207463-59-0 CAPLUS

CN Acetic acid, [2-(2-butoxy-2-oxoethoxy)-5-[1-hydroxy-2-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



IT 207463-40-9P 207463-47-6P 207463-48-7P

207463-58-9P


RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thienopyridine derivs. as antithrombotics)

RN 207463-40-9 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-(2-butoxy-2-oxoethoxy)-4-(3,3-dimethyl-2-oxobutoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 207463-41-0 CAPLUS


CN Acetic acid,

[2-(2-butoxy-2-oxoethoxy)-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 207463-37-4

CMF C24 H28 N2 O8 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 207463-42-1 CAPLUS

CN Acetic acid,


[2-(2-butoxy-2-oxoethoxy)-5-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)

L8 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 207463-47-6 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-(4-(2-butoxy-2-oxoethoxy)-3-hydroxyphenyl)-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 207463-48-7 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-(4-(2-butoxy-2-oxoethoxy)-3-(2-(1,1-dimethylethoxy)-2-oxoethoxy)phenyl)-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 207463-58-9 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-(4-(2-ethoxy-2-oxoethoxy)-3-(2-(9H-fluoren-9-ylmethoxy)-2-oxoethoxy)phenyl)-2-hydroxyethyl]amino]carbonyl]-6,7-dihydro-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1997:679074 CAPLUS  
 DOCUMENT NUMBER: 127:307400  
 TITLE: preparation of novel heterocyclic compounds having blood platelet aggregation inhibitory activity  
 INVENTOR(S): Yamamoto, Takehiro; Miura, Tomoaki; Isomura, Yasuko; Tadauchi, Kaori; Iida, Hiroyuki; Ouchi, Shokichi; Katano, Kiyooki  
 PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan  
 SOURCE: PCT Int. Appl., 82 pp.  
 CODEN: PIXKX2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736887	A1	19971009	WO 1997-JP1106	19970331
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9720442	A1	19971022	AU 1997-20442	19970331
EP 897920	A1	19990224	EP 1997-908555	19970331
R:	BE, DE, ES, FR, GB, IT			
PRIORITY APPLN. INFO.:			JP 1996-78004	A 19960329
			WO 1997-JP1106	W 19970331

OTHER SOURCE(S): MARPAT 127:307400  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [I; R1, R2 = H, (un)substituted lower alkyl; R3 = H, (un)substituted lower alkyl or Ph; R4 = aminomethyl, etc.; G, H, I, J = N, O, S, CO, etc.; K, L = H2, O; B = COCHR7, CONR7; R7 = H, lower alkyl; D = CO, CHOH, etc.; E = H, CH2Y; Y = pyridyloxy, pyridylalkyl, etc.; F = Z(CH2)qCO2R8, CH:CR9CO2R8; Z = O, bond; R8, R9 = H, lower alkyl, etc.; q = 1-4; p = 1-2] having platelet aggregation inhibitory effects, and pharmacol. acceptable salts and solvates thereof, are prepared Medicinal compns. containing I are utilizable as blood platelet aggregation inhibitors that are excellent in blood platelet aggregation inhibitory activities, do not cause hemorrhage and side effects due to a failure in the selectivity for inhibitory actions, and are also efficacious against vascular lesions such as vascular spasm. Thus, imidazole derivative (V; R5 = R6 = tert-Bu) (preparation given) was treated with anisole and CF3CO2H to give the title

L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 compd. V.CF3CO2H (R5 = R6 = H); which showed IC50 of 4.4  $\mu$ M against human blood platelet aggregation.  
 IT 197237-35-7P 197237-37-9P 197237-39-1P  
 197237-41-5P 197237-43-7P 197237-50-6P  
 197237-53-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of novel heterocyclic compds. having blood platelet aggregation inhibitory activity)  
 RN 197237-35-7 CAPLUS  
 CN Acetic acid, [2-[(1H-imidazol-1-yl)methyl]-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 197237-34-6  
 CMF C22 H22 N4 O5 S




CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 197237-37-9 CAPLUS  
 CN Acetic acid, [2-[(3-pyridinyloxy)methyl]-4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 197237-36-8  
 CMF C24 H23 N3 O6 S


L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 197237-39-1 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[1-(3-pyridinyloxy)-2-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]ethyl]-1,2-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 197237-38-0  
 CMF C25 H25 N3 O8 S




CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 197237-41-5 CAPLUS




L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Acetic acid, 2,2'-[[4-[[1-(3-pyridinyloxy)-2-[methyl[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]ethyl]-1,2-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 197237-40-4  
 CMF C26 H27 N3 O8 S



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 197237-43-7 CAPLUS  
 CN Acetic acid, [4-[[1-(3-pyridinyloxy)-2-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]ethyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 197237-42-6  
 CMF C23 H23 N3 O5 S




L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CRN 76-05-1  
 CMF C2 H F3 O2




IT 165948-12-9 197238-28-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 aggregation  
 inhibitory activity)

RN 165948-12-9 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-hydroxyethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 197238-28-1 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-hydroxyethyl]methylamino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 197237-66-4P 197237-67-5P 197237-68-6P  
 197237-69-7P 197237-70-0P 197237-71-1P  
 197237-72-2P 197237-73-3P 197237-75-5P  
 197237-76-6P 197238-08-7P 197238-10-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of novel heterocyclic compds. having blood platelet aggregation

L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 197237-50-6 CAPLUS  
 CN Acetic acid, [4-[[1-(3-pyridinyloxy)-2-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]ethyl]phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 197237-53-9 CAPLUS  
 CN Acetic acid, [4-[[2-[methyl[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]-1-(3-pyridinyloxy)ethyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1  
 CRN 197237-52-8  
 CMF C24 H25 N3 O5 S




CM 2

L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 inhibitory activity)


RN 197237-66-4 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 197237-67-5 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-(hydroxymethyl)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 197237-68-6 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[[methylsulfonyl]oxy]methyl]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 197237-69-7 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-(1H-imidazol-1-ylmethyl)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 197237-70-0 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-(3-pyridinyloxy)ethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 197237-71-1 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis(2-(1,1-dimethylethoxy)-2-oxoethoxy)phenyl]-2-(3-pyridinyloxy)ethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 197237-72-2 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[2-[[[5-(1,1-dimethylethoxy)-4,5,6,7-


L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 c]pyridin-2-yl]carbonyl]amino]-1-hydroxyethyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 197238-08-7 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-hydroxyethyl]methylamino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 197238-10-1 CAPLUS  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-(3-pyridinyloxy)ethyl]methylamino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]methylamino]-1-hydroxyethyl]-1,2-phenylene]bis(oxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 197237-73-3 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[2-[[[5-(1,1-dimethylethoxy)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]methylamino]-1-(3-pyridinyloxy)ethyl]-1,2-phenylene]bis(oxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 197237-75-5 CAPLUS  
 CN Acetic acid, 4-[[[5-(1,1-dimethylethoxy)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 197237-76-6 CAPLUS  
 CN Acetic acid, 4-[[[5-(1,1-dimethylethoxy)-4,5,6,7-tetrahydrothieno[3,2-

L8 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1996:741356 CAPLUS  
 DOCUMENT NUMBER: 126:54462  
 TITLE: Tetrahydrothienopyridine derivatives as novel GPIIb/IIIa antagonists  
 AUTHOR(S): Katano, Kiyooki; Shitara, Eiki; Shimizu, Masaro; Sasaki, Kazuo; Miura, Tomoaki; Isomura, Yasuko; Kawaguchi, Mami; Ohuchi, Shokichi; Tsuruoka, Takashi  
 CORPORATE SOURCE: Pharm. Res. Cent., Meiji Seika Kaisha Ltd., Yokohama, 222, Japan  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(21), 2601-2606  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The tetrahydrothienopyridine derivs. were derived from aminomethylcyclohexylcarboxylic acid as a lead moiety. Evaluation of the antiplatelet activity and receptor binding assay revealed that compound  
 ME 3277 was a novel and potent non-peptide and non-amidinophenyl GPIIb/IIIa antagonist.  
 IT 165948-72-1P, ME 3277 165948-87-8P 165948-89-0P  
 165948-93-6P 165948-97-0P 165948-99-2P  
 185245-56-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and antiplatelet activity of tetrahydrothienopyridine derivs. as GPIIb/IIIa antagonists)  
 RN 165948-72-1 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)




RN 165948-87-8 CAPLUS  
 CN Acetic acid, 4-[[[5-(1,1-dimethylethoxy)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 165948-89-0 CAPLUS  
 CN Acetic acid, 2,2'-[[5-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-


L8 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 185245-56-1 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,3-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)




RN 165948-93-6 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydro-3-methylthieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RN 165948-97-0 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydro-3-(phenylmethyl)thieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RN 165948-99-2 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydro-3-(phenylmethyl)thieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)




L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1995:723127 CAPLUS  
 DOCUMENT NUMBER: 123:143870  
 TITLE: preparation of novel heterocyclic compounds as platelet aggregation inhibitors  
 INVENTOR(S): Katano, Kiyooki; Ohuchi, Shokichi; Shitara, Eiki; Shimizu, Masaro; Yaegashi, Kazuo; Miura, Tomoaki; Isomura, Yasuko; Iida, Hiroyuki; Ishikawa, Midori; et al.  
 PATENT ASSIGNEE(S): Meiji Seika K. K., Japan  
 SOURCE: PCT Int. Appl., 190 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9421599	A1	19940929	WO 1994-JP437	19940317
W: AU, CA, CN, JP, KR, NO, NZ, US				
CA 2136007	AA	19940929	CA 1994-2136007	19940317
CA 2136007	C	19991214		
AU 9462638	A1	19941011	AU 1994-62638	19940317
AU 688756	B2	19980319		
EP 641770	A1	19950308	EP 1994-910038	19940317
EP 641770	B1	19980513		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1107277	A	19950823	CN 1994-190209	19940317
CN 1045084	B	19990915		
AT 166047	E	19980515	AT 1994-910038	19940317
ES 2117264	T3	19980801	ES 1994-910038	19940317
NO 9404371	A	19950113	NO 1994-4371	19941116
NO 308607	B1	20001002		
US 5594004	A	19970114	US 1995-347402	19950130
US 5698692	A	19971216	US 1996-733743	19961018
AU 9852084	A1	19980319	AU 1998-52084	19980115
AU 723180	B2	20000817		

PRIORITY APPLN. INFO.:  
 JP 1993-57463 A 19930317  
 JP 1993-82145 A 19930408  
 JP 1993-265273 A 19931022  
 WO 1994-JP437 W 19940317  
 US 1995-347402 A3 19950130




OTHER SOURCE(S):  
 GI MARPAT 123:143870

L8 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 185245-56-1 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Heterocyclic compds. [I; A = thienopyridinyl, substituted cyclohexyl, piperidinyl, etc.; BY = CONHCH2CO, CONHCH2CH2, etc.; R1, R2 = OCH2CO2H, salts, esters, etc.; X = CH, N] are prepared A mixture of II (preparation given), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate, and N-methylmorpholine was stirred at room temperature, III (preparation given) was added, and the mixture was stirred at room temperature to give 50.9% ester IV (R = Me3C, R3 = CO2Me3), which was stirred with anisole and CF3CO2H at room temperature to give 97.3% salt IV.CF3CO2H (R = R3 = H) (V). V showed IC50 of 0.14 μM against ADP-induced platelet aggregation in human.  
 IT 165948-73-2P 165948-82-3P 165948-88-9P 165948-90-3P 165948-92-5P 165948-94-7P 165948-96-9P 165948-98-1P 165949-00-8P 165949-14-4P 165949-20-2P 165949-28-0P 165949-30-4P 165949-32-6P 165949-35-9P 165949-37-1P 165949-41-7P 165949-42-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of novel heterocyclic compds. as platelet aggregation inhibitors)  
 RN 165948-73-2 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
 CRN 165948-72-1  
 CMF C20 H20 N2 O8 S

L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 165948-82-3 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[methyl(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]-1,2-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165948-81-2  
CMF C21 H22 N2 O8 S



CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 165948-88-9 CAPLUS  
CN Acetic acid, [4-[[[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 165948-92-5 CAPLUS  
CN Acetic acid, [3-[[[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165948-91-4  
CMF C18 H18 N2 O5 S




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 165948-94-7 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]-1,3-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165948-93-6  
CMF C20 H20 N2 O8 S



L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1  
CRN 165948-87-8  
CMF C18 H18 N2 O5 S




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 165948-90-3 CAPLUS  
CN Acetic acid, 2,2'-[[5-[[[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]-1,3-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165948-89-0  
CMF C20 H20 N2 O8 S



CM 2  
CRN 76-05-1  
CMF C2 H F3 O2


L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 165948-96-9 CAPLUS  
CN Acetic acid, [3-methoxy-4-[[[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165948-95-8  
CMF C19 H20 N2 O6 S




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 165948-98-1 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[[[4,5,6,7-tetrahydro-3-methylthieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]-1,2-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165948-97-0  
CMF C21 H22 N2 O8 S

L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 165949-00-8 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydro-3-(phenylmethyl)thieno[3,2-c]pyridin-2-yl]carbonylamino]acetyl]-1,2-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165948-99-2  
CMF C27 H26 N2 O8 S



CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 76-05-1  
CMF C2 H F3 O2



RN 165949-28-0 CAPLUS  
CN Acetic acid, [2-propoxy-4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonylamino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165949-27-9  
CMF C21 H24 N2 O6 S



CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 165949-30-4 CAPLUS  
CN Acetic acid, [2-(phenylmethoxy)-4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonylamino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165949-29-1  
CMF C25 H24 N2 O6 S

L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 165949-14-4 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonylamino]acetyl]-1,2-phenylene]bis(oxy)]bis-, bis[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl] ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165949-13-3  
CMF C30 H28 N2 O14 S




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 165949-20-2 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[1-hydroxy-2-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonylamino]ethyl]-1,2-phenylene]bis(oxy)]bis-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1  
CRN 165949-19-9  
CMF C20 H22 N2 O8 S



CM 2

L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 165949-32-6 CAPLUS  
CN Acetic acid, [2-(carboxymethoxy)-5-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonylamino]acetyl]phenoxy]-, 1-ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1  
CRN 165949-31-5  
CMF C22 H24 N2 O8 S



CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 165949-35-9 CAPLUS  
CN Acetic acid, [2-hydroxy-4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-

L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
yl)carbonylamino]acetyl]phenoxy]-, mono(trifluoroacetate) (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 165949-34-8  
CMF C18 H18 N2 O6 S



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 165949-37-1 CAPLUS  
CN Acetic acid, 2'-[[4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 165949-36-0  
CMF C21 H23 N3 O7 S



CM 2


CRN 76-05-1  
CMF C2 H F3 O2

L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


IT 165947-43-3P 165947-90-0P 165947-93-3P  
165947-94-4P 165947-95-5P 165947-96-6P  
165947-97-7P 165947-98-8P 165947-99-9P  
165948-02-7P 165948-03-8P 165948-09-4P  
165948-10-7P 165948-12-9P 165948-28-7P  
165948-30-1P 165948-31-2P 165948-34-5P  
165948-35-6P 165948-47-0P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of novel heterocyclic compds. as platelet aggregation inhibitors)


RN 165947-43-3 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 165947-90-0 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-oxoethyl]methylamino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 165947-93-3 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 165949-41-7 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]-1,2-phenylene]bis(oxy)]bis-, dibutyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 165949-40-6  
CMF C28 H36 N2 O8 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 165949-42-8 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonylamino]acetyl]-1,2-phenylene]bis(oxy)]bis-, dicyclohexyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 165947-94-4 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,5-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 165947-95-5 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165947-96-6 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[2,4-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165947-97-7 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-methoxyphenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)







RN 165947-98-8 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis(2-(1,1-dimethylethoxy)-2-oxoethoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-3-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 165947-99-9 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis(2-(1,1-dimethylethoxy)-2-oxoethoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-3-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165948-02-7 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[[5-(1,1-dimethylethyl)-4',5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




PAGE 1-B




RN 165948-12-9 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-2-hydroxyethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165948-28-7 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-propoxyphenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165948-03-8 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis(2-ethoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165948-09-4 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis(carboxymethoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 5-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 165948-10-7 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis(2-oxo-1,3-dioxol-4-ylmethoxy)-2-oxoethoxy]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165948-30-1 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-hydroxyphenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 165948-31-2 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-(phenylmethoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165948-34-5 CAPLUS  
CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-(2-ethoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 165948-35-6 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[(ethylamino)carbonyloxy]phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 165948-47-0 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[3,4-bis(2-butoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
78.49	303.22

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-11.25	-11.25

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 12:32:27 ON 26 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 OCT 2006 HIGHEST RN 911284-77-0

DICTIONARY FILE UPDATES: 25 OCT 2006 HIGHEST RN 911284-77-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10662135.str



chain nodes :

7 8 9 10 11 13 18 21 22 23 24 28 29 30

ring nodes :

1 2 3 4 5 6

chain bonds :

6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 13:CLASS 18:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:Atom  
28:CLASS 29:CLASS 30:CLASS

Generic attributes :

18:

Number of Carbon Atoms : 7 or more


Number of Hetero Atoms : 2 or more

Type of Ring System : Polycyclic

Element Count :  
Node 18: Limited  
O,O0  
S,S1  
N,N1  
C,C7

L9 STRUCTURE UPLOADED

=> d  
L9 HAS NO ANSWERS  
L9 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s 19  
SAMPLE SEARCH INITIATED 12:32:48 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2057 TO ITERATE

97.2% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 38420 TO 43860  
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> s 19 full

FULL SEARCH INITIATED 12:32:52 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 39731 TO ITERATE

100.0% PROCESSED 39731 ITERATIONS



0 ANSWERS

SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L9

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10662135.str



chain nodes :

7 8 9 10 11 13 18 21 22 23 24 28 29 30

ring nodes :

1 2 3 4 5 6

chain bonds :

6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 13:CLASS 18:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:Atom  
28:CLASS 29:CLASS 30:CLASS

Generic attributes :

18:

Number of Carbon Atoms : 7 or more

Number of Hetero Atoms : 2 or more

Type of Ring System : Polycyclic

Element Count :

Node 18: Limited

O,O0

S,S1

N,N1


C,C7

L12 STRUCTURE UPLOADED

=> d

L12 HAS NO ANSWERS

L12 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l12

SAMPLE SEARCH INITIATED 12:33:27 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 29704 TO ITERATE

6.7% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 583774 TO 604386  
PROJECTED ANSWERS: 0 TO 0

L13 0 SEA SSS SAM L12

=> s l12 full  
FULL SEARCH INITIATED 12:33:33 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 589723 TO ITERATE


96.1% PROCESSED 567010 ITERATIONS 1 ANSWERS

100.0% PROCESSED 589723 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.27

L14 1 SEA SSS FUL L12

=> d

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN 197237-77-7 REGISTRY  
 ED Entered STN: 13 Nov 1997  
 CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[2-[4-[3-(1,1-dimethylethoxy)-2,3-dioxopropoxy]phenyl]-2-(3-pyridinyloxy)ethyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (SCI) (CA INDEX NAME)  
 MF C33 H39 N3 O8 S  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10662135.str



chain nodes :

7 8 9 10 11 13 18 21 22 23 24 28 29 30

ring nodes :

1 2 3 4 5 6

chain bonds :

6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

6-7 7-8 8-9 8-13 9-10 10-11 11-18 21-30 22-24 22-23 22-28 28-29 29-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:CLASS 13:CLASS 18:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:Atom

28:CLASS 29:CLASS 30:CLASS

Generic attributes :

18:

Number of Carbon Atoms : 7 or more

Number of Hetero Atoms : 2 or more




Type of Ring System : Polycyclic

Element Count :  
Node 18: Limited  
O,O0  
S,S1  
N,N1  
C,C7

L15 STRUCTURE UPLOADED

=> d  
L15 HAS NO ANSWERS  
L15 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l15  
SAMPLE SEARCH INITIATED 12:35:21 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 26736 TO ITERATE

7.5% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 524939 TO 544501  
PROJECTED ANSWERS: 0 TO 0

L16                    0 SEA SSS SAM L15

=> s l15 full

FULL SEARCH INITIATED 12:35:24 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 532752 TO ITERATE

96.8% PROCESSED      515737 ITERATIONS

0 ANSWERS

100.0% PROCESSED      532752 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.26

L17                    0 SEA SSS FUL L15

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

504.04

807.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-11.25

STN INTERNATIONAL LOGOFF AT 12:35:55 ON 26 OCT 2006

This Page is inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images  
problems checked, please do not report the  
problems to the IFW Image Problem Mailbox**